NASDAQ: APREAprea Therapeutics Inc Stock
$0.78+0.01 (+1.3%)
Updated Sep 14, 2026
APRE Price
$0.78
Fair Value Price
$2.23
Market Cap
$9.83M
52 Week Low
$0.55
52 Week High
$1.69
P/E
-0.75x
P/B
0.26x
P/S
8,023x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.19k
Earnings
-$12.31M
Gross Margin
100%
Operating Margin
-245,156.76%
Profit Margin
-237,362.8%
Debt to Equity
0.1
Operating Cash Flow
-$12M
Beta
0.6
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
APRE Overview
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine APRE's potential to beat the market
- APRE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
APRE
RankedUnranked of 459
RankedUnranked of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.14 | A | |
| $6.85 | A | |
| $41.54 | A |
Be the first to know about important APRE news, forecast changes, insider trades & much more!
APRE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APRE ($0.78) is undervalued by 65.02% relative to our estimate of its Fair Value price of $2.23 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
APRE ($0.78) is significantly undervalued by 65.02% relative to our estimate of its Fair Value price of $2.23 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
APRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APRE due diligence checks available for Premium users.
Valuation
APRE fair value
Fair Value of APRE stock based on Discounted Cash Flow (DCF)
Price
$0.78
Fair Value
$2.23
Undervalued by
65.07%
APRE ($0.78) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APRE ($0.78) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APRE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.75x
Industry
8.25x
Market
43.6x
APRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.26x
Industry
5.35x
APRE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APRE's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.6M
Profit Margin
0%
APRE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
APRE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$42.3M
Liabilities
$3.8M
Debt to equity
0.1
APRE's short-term assets ($41.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APRE's short-term assets ($41.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APRE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
APRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.3M
Investing
$0.0
Financing
-$1.9M
APRE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APRE vs Biotech Stocks
Aprea Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.